Basel, Switzerland (ots/PRNewswire) - - Anti-Angiogenic Treatment Shows Survival Benefit Across Three Major Cancer Types: Breast, Lung And Colorectal Cancer A new study with Avastin(R) (bevacizumab, rhuMAb-VEGF) today reported that when used in combination with chemotherapy, Avastin doubled the chances of ...
Basel, Switzerland (ots/PRNewswire) - - Addition of Avastin Boosts Efficacy of First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer A new study, presented for the first time today, reveals that Avastin(R) (bevacizumab rhuMAb-VEGF) significantly extends survival for patients with previously untreated, advanced non-small cell lung cancer (NSCLC), ...
Milan, Italy (ots/PRNewswire) - - Net Revenues Grow to 179.3 Million Euros in the First Quarter of 2005, or 1.8% More Than in the Same Period Last Year.(1) - EBITDA Total 16.5 Million Euros, Compared With 18.2 Million Euros in 2004, Improving 5.1% vs. Same Period Last Year (net of Exceptional Items of 2.5 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. The planned randomized, open-label trial will include approximately 332 de novo (newly ...
Montreal, Canada (ots/PRNewswire) - Genizon BioSciences, Inc., a Montreal-based gene and drug target discovery company, announced today it has acquired the majority of the assets and staff of Sweden-based Global Genomics AB. Through this transaction, Genizon has gained access to a novel sequencing technology, ...
Espoo, Finland (ots/PRNewswire) - Net sales of the Orion Group were EUR 465.3 (496.9) million, down by 6.4% due to decreased invoicing of the pharmaceutical distribution business. Group operating profit grew by 52.2% to EUR 50.8 (33.4) million, thanks to the favourable performance of Orion Pharma. Group profit before taxes was EUR 50.6 (33.0) million. Earnings per share were EUR 0.27 (0.17). Equity ratio was 40.7% ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company will web cast its Annual General Meeting in Toronto on Tuesday, May 10, 2005 at 10:00 a.m. EDT. The web cast will include corporate and scientific updates. The web cast will be chaired by Dr. Robert Foster, Chairman and CEO; with Dr. Randall Yatscoff, President and COO presenting the scientific update. Interested parties can ...
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. announced today that the Company has received the first tranche of a CDN $15 million financing. The funds will be used by Cytochroma to continue advancement of CTA018 towards a Phase II clinical trial for psoriasis as well as to extend its pipeline of late-stage preclinical products. This recent round of financing was led by VenGrowth Private Equity Partners Inc. ...
Amsterdam, Netherlands (ots/PRNewswire) - - Hospira Healthcare B.V. will also serve as regional headquarters for Europe, Middle East and Africa -- Today Hospira, Inc. (pronounced Hos-PEER-ah), a global independent specialty pharmaceutical and medication delivery company created in April 2004 from the core global hospital products business of Abbott Laboratories, announced that it has established its presence ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. This randomized, open-label trial will include approximately 332 de novo (newly transplanted) kidney patients. Patients ...
Madrid (ots/PRNewswire) - PharmaMar: - Zalypsis: this is PharmaMar's fifth compound to reach clinical development. - Aplidin: commenced Phase II studies on prostate and bladder cancer. - Yondelis: pivotal Phase III studies commenced on ovarian cancer patients. NeuroPharma: - Presented pre-clinical data at the 7th International Conference on Alzheimer's and Parkinson's Disease. Other: - ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to show promising results. The Canadian Phase III Psoriasis trial (SPIRIT) which commenced on December 2, 2004, includes a total of 453 patients with stable moderate to severe plaque psoriasis. The trial is currently being conducted in 32 sites and ...
New Brunswick, New Jersey and Indianapolis (ots/PRNewswire) - Johnson & Johnson and Guidant Corporation today announced that they have been notified, as anticipated, that the European Commission has decided to open a second phase review into the proposed acquisition of Guidant by Johnson & Johnson. The companies ...
Montreal, Canada (ots/PRNewswire) - Genizon BioSciences today announced the confirmation of a previously reported disease-gene location, PSORS1, as well as the identification of more than 10 new regions strongly associated with psoriasis, each containing only a limited number of genes. The company will be discussing with potential pharmaceutical partners how ...
Seattle and Mountain View, California (ots/PRNewswire) - - MPEG-4 aacPlus Provides High Quality Cross-Platform Support for PCs and Mobile Phones Loudeye Corp. (Nasdaq: LOUD), a worldwide leader in business-to-business digital media solutions, and Coding Technologies announced today that Loudeye is deploying Coding Technologies MPEG-4 aacPlus audio format ...
New York (ots/PRNewswire) - Genesis Bioventures, Inc. (AMEX:GBI) (GBI) today reported that its Annual Report on Form 10-KSB for the year ended December 31, 2004 was not filed by the deadline of Friday, April 15, 2005. The Company expects to file the 2004 annual report on or before May 15, 2005. GBI explained that the delay in filing was caused by the termination ...
Anaheim, California (ots/PRNewswire) - PharmaMar today announces the presentation of thirteen posters highlighting advances with its clinical and preclinical compounds at the 96th Annual Meeting of the American Association for Cancer Research (AACR), taking place in Anaheim, California from 16-20 April 2005. The posters include results from research on Yondelis(R), ...
Reykjavik, Iceland (ots/PRNewswire) - Theriak Medication Management, a software system from TM Software for use in healthcare operations, went into commission yesterday at a central hospital pharmacy in Bottrop, a city in the Rühr district in Germany. The pharmacy serves hospitals in the nearby cities of Oberhausen and Gelsenkirchen, which together have about five hundred in-patient beds. Spokesmen at the pharmacy say ...
Espoo, Finland (ots/PRNewswire) - The operating profit of the Orion Group for the first quarter of 2005 seems to be clearly better than that in the comparative period last year, for which the consolidated operating profit in accordance with the IFRS came to EUR 33.4 million. The good profitability is mainly consequence of the continued good sales performance and successful cost management in the Orion Pharma business division. Also the full-year net sales and ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that its marine-derived anti-cancer drug, YONDELIS(R) (trabectedin), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ovarian cancer. The U.S. application sponsor, is Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Company has been issued U.S. Patent No. 6,878,550 for its diagnostic breath test kit, Diatest(R). The patent entitled "13C Glucose Breath Test for the Diagnosis of Diabetic Indications and Monitoring Glycemic Control" is the fifth U.S. Patent issued for this technology. ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Major U.S. Public Health Initiative Complements sanofi pasteur's Leadership in Global Pandemic Preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract from the U.S. Health ...
Lyon, France (ots/PRNewswire) - - First New Vaccine Against Polio in Decades to Be Used in Egypt, Part of Innovative WHO Strategy Sanofi pasteur, the vaccines business of the sanofi-aventis group, has received a license from the Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) for a new polio vaccine, which is the first new vaccine ...
Espoo, Finland (ots/PRNewswire) - At its meeting held yesterday evening, the Board of Directors of Orion Corporation, which was elected yesterday at the Annual General Meeting of Shareholders, has re-elected Erkki Etola as Vice Chairman. Orion Corporation Jukka Viinanen Olli Huotari President and CEO General Counsel ...
Princeton, New Jersey (ots/PRNewswire) - BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL-5 receptor antibody, a potential new asthma treatment. Under the terms of the ...
Espoo, Finland (ots/PRNewswire) - At the Annual General Meeting of Orion Corporation held today, the following decisions were made: - A dividend of EUR 0.55 per share will be paid for 2004, payment date 5 April 2005. - Seven Board members were elected in accordance with the proposal by Board of Directors. Erkki Etola, Eero Karvonen, Matti Kavetvuo, Leena Palotie, Vesa Puttonen and Heikki Vapaatalo were ...
Espoo, Finland (ots/PRNewswire) - In his presentation of the 2004 Financial Statements to the Annual General Meeting of Orion Corporation, starting at 5 pm today in Helsinki, Mr. Jukka Viinanen, CEO of the Orion Group, will inform that the profitability of the Orion Group has shown very positive development in the first months of 2005 compared to the corresponding ...
Lyon, France (ots/PRNewswire) - - Vaccine Leader Looks to Introduce First Pertussis Booster for Both Adolescents and Adults in United States Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee ...
Istanbul, Turkey (ots/PRNewswire) - The inventor of extracorporeal shockwave lithotripsy (ESWL), Dornier MedTech, introduces the Compact Delta II lithotripter during the 20th annual European Association of Urology meeting. The Compact Delta II is based upon superior technology from the most widely sold lithotripter to date, the Compact Delta. This ...
Paris (ots/PRNewswire) - - New Indication Means More Patients Could Benefit From Earlier Treatment Bristol-Myers Squibb announces the approval of Taxol(r) (paclitaxel) for the treatment of early stage node-positive breast cancer following standard anthracycline and cyclophosphamide (AC) therapy. According to the approval, adjuvant treatment with Taxol should ...